Combined effects of a third-generation bisphosphonate, zoledronic acid with other anticancer agents against murine osteosarcoma

Bisphosphonates (BPs) are widely used to treat bone diseases and also appear to possess direct antitumour activity. We have previously reported that third-generation BPs such as zoledronic acid (ZOL) and minodronic acid (YM529) synergistically augment the effects of anticancer agents in various canc...

Descripción completa

Detalles Bibliográficos
Autores principales: Horie, N, Murata, H, Kimura, S, Takeshita, H, Sakabe, T, Matsui, T, Maekawa, T, Kubo, T, Fushiki, S
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2007
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360011/
https://www.ncbi.nlm.nih.gov/pubmed/17242698
http://dx.doi.org/10.1038/sj.bjc.6603548

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360011/
https://www.ncbi.nlm.nih.gov/pubmed/17242698
http://dx.doi.org/10.1038/sj.bjc.6603548

Ejemplares similares